News

Sangamo and Biogen are partnering up to develop gene therapies for Alzheimer’s and Parkinson’s disease, as well as another neuromuscular disease target and up to nine undisclosed neurological disorders. Initially, the collaboration will focus on two molecules in Sangamo’s pipeline: ST-501 for tauopathies such as Alzheimer’s, ST-502…

In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them rare. Running Feb. 7–29, the #WhatMakesMeRare campaign was aimed at uplifting people with rare diseases by encouraging them to share their stories and perspectives. The…

The number of commercially insured U.S. residents diagnosed with early onset dementia and Alzheimer’s disease (AD) rose by 200% from 2013 to 2017, and the average age of a person living with either condition was 49, according to a new Blue Cross Blue Shield Association (BCBSA)…

A Temple University researcher has been awarded a $500,000 two-year grant to develop a treatment that targets chronic brain inflammation and other disease characteristics in Alzheimer’s. Silvia Fossati, associate director of the Alzheimer’s Center at Temple Health’s Lewis Katz School of Medicine, will work with pharmaceutical…

Researchers have found that amyloid, the protein that forms toxic aggregates, or clumps in the brain and is thought to be involved in the onset of Alzheimer’s disease (AD), accumulates faster in people with subtle cognitive difficulties compared with cognitively normal people. These findings suggest that measurements of…

DNA from various species of bacteria, some of which — like E. coli — have been identified in the brains of Alzheimer’s patients, can cause the tau protein to fold incorrectly and form the toxic, clump-like structures increasingly thought to play a key role in disease progression. The study…

A new biosensor using neatly aligned carbon nanotubes may bring scientists one step closer to a blood test for the early detection of Alzheimer’s disease. The nanotubes were able to measure microscopic concentrations of Alzheimer’s main protein biomarkers in blood plasma, and reportedly distinguished Alzheimer’s patients from healthy…

A Phase 2 clinical trial testing Annovis Bio’s oral therapy ANVS401 (also known as Posiphen) in people with early Alzheimer’s disease can continue without changes, according to a positive review by the study’s independent Data Safety Monitoring Board (DSMB). The DSMB reviewed safety data, enrollment, participant status,…

Two investigational treatments, solanezumab and gantenerumab, failed to prevent memory loss or cognitive decline in patients with a rare, inherited form of early-onset Alzheimer’s disease, who were enrolled in a Phase 2/3 clinical trial (NCT01760005). Despite these results, the data collected will prove useful for identifying…

Biogen will soon launch an open-label trial to start re-dosing aducanumab  — an injectable treatment under development — to patients with Alzheimer’s disease who participated in four studies halted in March 2019. The company said it submitted the protocol of the re-dosing study to the U.S.